ATLASSpyre Therapeutics (SYRE) earnings date: Nov 3, 2026
Spyre Therapeutics (SYRE) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 3, 2026, after the close. Analysts expect EPS of -$0.79.
Source: company filings and exchange data · Updated Nov 2, 2026
Spyre Therapeutics reports on Nov 3, 2026. One email the day before, with ATLAS’s read on Spyre Therapeutics. You can switch it off at any time.
Alert me before SYRE reportsFree to start. Creating an account takes under a minute.
SYRE earnings at a glance
| Next report (confirmed) | Tue, Nov 3, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.79 |
| Last report | Aug 4, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +31.3% |
| Average move around a report | ±7.7% (last 5) |
| Sector | Healthcare · Biotechnology |
Spyre Therapeutics earnings history: last 5 reports
Spyre Therapeutics last reported on Aug 4, 2026: EPS of -$0.36 against an estimate of -$0.75 (+52.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 4, 2026 | -$0.75 | -$0.36 | +52.0% | Beat | +9.9% |
| May 5, 2026 | -$0.65 | -$0.74 | -13.9% | Miss | +5.6% |
| Feb 19, 2026 | -$0.80 | -$0.74 | +7.5% | Beat | +18.1% |
| Nov 4, 2025 | -$0.74 | -$0.15 | +79.7% | Beat | -3.9% |
| Aug 5, 2025 | -$0.71 | -$0.49 | +31.0% | Beat | -1.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
ATLAS view on SYRE before the report
| Last price | $96.56 (-2.4%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 47% |
| Likely 1-month range (50%) | $84.90 – $107.01 |
| Normal 1-day range (±1σ) | ±3.9% |
These figures come from the same calibrated model and valuation as the Spyre Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Get the full ATLAS analysis for SYRE
See the fair value, the probability range and the earnings history of Spyre Therapeutics on its ATLAS page.
Spyre Therapeutics (SYRE) stock analysisPlans from €3.99 a month.
Spyre Therapeutics earnings: frequently asked questions
When does Spyre Therapeutics (SYRE) report earnings?
Spyre Therapeutics is scheduled to report on Tuesday, November 3, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for SYRE?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.79 per share (USD). Estimates can change before the report.
How often does SYRE beat earnings estimates?
Of its last 5 reports with a recorded result, Spyre Therapeutics beat the EPS estimate 4 times; the average surprise was +31.3%. Past results do not predict the next one.
How much does SYRE move around earnings?
Over its last 5 reports the stock moved an average of 7.7% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Spyre Therapeutics beat earnings estimates last quarter?
Spyre Therapeutics last reported on Aug 4, 2026: EPS of -$0.36 against an estimate of -$0.75 (+52.0% surprise), a beat.
How much does SYRE usually move in a day?
On a normal trading day the ATLAS model puts SYRE’s one-day range at about ±3.9%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 3, 2026
Educational information, not investment advice. Disclaimer